Health Condition 1: null- Patients having oral Lichen planus lesions and without any severe debilitating medical illness
Conditions
Interventions
Intervention1: â?¢ Topical Pimecrolimus, Oral Mycophenolate mofetil alongwith topical Pimecrolimus, Patients on oral Methotrexate alongwith topical Pimecrolimus.
: pimecrolimus: was prescribed as 1%
Sponsors
Maulana Azad Institute of Dental Science
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients older than 8 years with histologically proven Lichen Planus cases, were included in the study.
Exclusion criteria
Exclusion criteria: 1. Lichenoid contact reaction due to any medication, mouthrinse, toothpaste or any other agent. 2. Patients who had received any therapy for Lichen Planus within past 8 weeks. 3. Any malignant or viral involvement in mouth . 4. Pregnant or nursing women also excluded. 5. Patients not willing to participate in the study 6. Patients whose complete follow up is lacking
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| As serum IL-6 levels significantly decreased in MMF group, correspondingly no resistance to treatment was noted. However with MTX there was no significant decrease in IL-6 and resistance to treatment was noted in some, especially plaque type lesions. Thus IL-6 can be a possible biomarker in deciding the best possible therapy for treatment resistant OLP.Timepoint: after 6 months period | — |
Primary
| Measure | Time frame |
|---|---|
| To compare therapeutic potential of Pimecrolimus, Mycophenolate mofetil and Methotrexate in oral lichen planus(OLP)using IL-6 as a marker of infllammatory Response and Cdk4 & p16 as markers of malignant potential. Timepoint: 3 months 6 months and 9th month | — |
Countries
India
Contacts
Public ContactSinny Goel
Head of Dept. OMDR, Maulana Azad Institute of Dental Sciences, Delhi
Outcome results
None listed